$VTVT News
Last published 1w ago
- 1w agoVTVTvTv Therapeutics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoVTVTvTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 Randomized the first participant in its
- 2w agoVTVTvTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery SystemsGlobeNewswirePhase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the
- 4w agoVTVTAPMDVEEViOnctura appoints Paul Sekhri as Chair of its Board of DirectorsGlobeNewswirePaul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercializationAppointment comes as iOnctura prepares for late-stage
- 1mo agoVTVTvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026GlobeNewswireHIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D),
- 1mo agoVTVTvTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseGlobeNewswireHIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D),
- 1mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 2mo agoVTVTvTv Therapeutics to Participate in September Investor ConferencesGlobeNewswireHIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D),
- 2mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 3mo agoVTVTvTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to
- 3mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 4mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 5mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 6mo agoVTVTvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, 2026 (GLOBE
- 6mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 6mo agoVTVTvTv Therapeutics to Participate in Upcoming May Investor ConferencesGlobeNewswireHIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 7mo agoVTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireHIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 8mo agoVTVTvTv Therapeutics to Participate in the 38th Annual ROTH ConferenceGlobeNewswireHIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 8mo agoVTVTvTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireReceived $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance sheet provides
- 9mo agoVTVTvTv Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireHIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 9mo agoVTVTvTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737GlobeNewswireStrategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment
- 10mo agoVTVTvTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of HealthGlobeNewswireHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42's
- 1y agoVTVTvTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireTopline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S.
- 1y agoVTVTvTv Therapeutics Announces New Appointments to its Scientific Advisory BoardGlobeNewswireHIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso
- 1y agoVTVTvTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual MeetingGlobeNewswireHIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational
- 1y agoVTVTUPDATE -- vTv Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireHIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 1y agoVTVTvTv Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireHIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral
- 1y agoVTVTvTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D FundGlobeNewswireProceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes
- 1y agoVTVTvTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual property portfolio
- 1y agoVTVTvTv Therapeutics Announces USPTO Allowance of Patent Covering CadisegliatinGlobeNewswireHIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive
- 1y agoVTVTvTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 DiabetesGlobeNewswireHIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes,
- 1y agoVTVTvTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" SeriesGlobeNewswireHIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral
- 1y agoVTVTvTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to InsulinGlobeNewswireHIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and
- 1y agoVTVTvTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireOngoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) --
- 1y agoVTVTvTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 DiabetesGlobeNewswireTopline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics
- 1y agoVTVTvTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateGlobeNewswireClinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin
- 1y agoVTVTvTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for DiabetesGlobeNewswireCadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial
- 1y agoVTVTCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCERPR NewswireCantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...
- 1y agoVTVTvTv Therapeutics to Participate in 7th Annual Evercore HealthCONx ConferenceGlobeNewswireHIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today
- 2y agoVTVTvTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireHIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today
- 2y agoVTVTvTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswireScreened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective
- 2y agoVTVTvTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical HoldGlobeNewswireHIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes,
- 2y agoVTVTvTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 DiabetesGlobeNewswireCadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over 500
- 2y agoVTVTCANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETINGPR NewswireCantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...
- 2y agoVTVTCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCERPR NewswireCantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other...
- 2y agoVTVTvTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireHIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of
- 2y agoVTVTCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITPR NewswireCantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other...
- 2y agoVTVTvTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateGlobeNewswireRecently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy to insulin,
- 2y agoVTVTvTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesGlobeNewswireHIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to
- 2y agoVTVTvTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewswireHIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to